Chronic anticoagulation options...the new drugs. How do we interpret/compare???
False
General clinical
Chronic anticoagulation options...the new drugs. How do we interpret/compare???
Discuss any specialty in this open forum for all healthcare professionals
What are the thoughts about the new options for patients who need chronic anticoagulation? Can anyone help me tease out the important info from the RELY and ROCKET studies (patients with A Fib)?
0
Cat:OpenClinicalForum:GeneralClinical
Cat:OpenClinicalForum:GeneralClinicalDiscussion:2b2c8e6c-545a-4aed-9a6c-ab64b6eff095
Forums » Open clinical » General clinical » Chronic anticoagulation options...the new drugs. How do we interpret/compare???
Forums
»
Open clinical
»
General clinical
»
Chronic anticoagulation options...the new drugs. How do we interpret/compare???
|
Chronic anticoagulation options...the new drugs. How do we interpret/compare???
posted at 13/2/2011 6:36 PM GMT
on bmj.com
|
Posts: 1
First: 13/2/2011 Last: 13/2/2011 |
What are the thoughts about the new options for patients who need chronic anticoagulation? Can anyone help me tease out the important info from the RELY and ROCKET studies (patients with A Fib)? Which one provides the most compelling data set? Are there any significant differences between rivaroxaban and dabigatran? Most anything is better than warfarin - but at least I know how to use it ... |
|
Re: Chronic anticoagulation options...the new drugs. How do we interpret/compare???
posted at 13/2/2011 7:29 PM GMT
on bmj.com
|
Posts: 1219
First: 19/4/2010 Last: 20/6/2013 |
I agree completely with the statement that anything must be better than warfarin. I think these new drugs can't be licensed in the UK soon enough. |
|
|
Re: Chronic anticoagulation options...the new drugs. How do we interpret/compare???
posted at 17/12/2011 11:45 PM GMT
on bmj.com
|
Posts: 627
First: 13/4/2011 Last: 18/6/2013 |
Hi All: These new oral anti-coagulants are trying to become a panacea for all pro-thrombotic states and to dominate the huge and expanding market of patients with atrial fibrillation. The clinical trials with them that I am aware of, are all non-inferiority trial, and sponsored by the manufacturers of these drugs. There is no known antidote for them. And there are appearing suspicious death reports in some countries like Japan, and I guess, in the USA. All Best, Joey
|
|
|
Re: Chronic anticoagulation options...the new drugs. How do we interpret/compare???
posted at 18/12/2011 3:33 PM GMT
on bmj.com
|
|
Posts: 897
First: 17/6/2011 Last: 17/6/2013 |
I agree with Joey R - the only drug that really seems to show promise is apixaban (look up the Aristotle trial).With regards to the others the key questions to my mind are 1. is the patient well controlled on warfarin? 2 What is the bleeding risk 3. How likely are you to want to reverse the drug? the more you say yes the less you should prescribe the new drugs! sadian |
|
|
Re: Chronic anticoagulation options...the new drugs. How do we interpret/compare???
posted at 29/12/2011 4:15 PM GMT
on bmj.com
|
Posts: 10
First: 7/4/2010 Last: 9/2/2012 |
Here is a nice article about the two: Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124:1573–1579. I am a senior resident in neurosurgery, and my concern is how easy we can reverse the effect, like said by sadian. For rivaroxaban this can be done with Cofact, but for dagibatran it seems to be a problem... I am afraid people will get killed if they suffer a intracranial hemorrhage while on this drug. And of course, that is not communicated in the Pradaxa (dagibatran) ads. Pieter Kubben, MD |
Forums » Open clinical » General clinical » Chronic anticoagulation options...the new drugs. How do we interpret/compare???
